Summary
Severe ocular disorders are affecting the lives of more than 100Mill people world-wide and at least 25% of the population above 70 years of age, a growing demographic group in EU. More than 8 million people lose their lives to cancer every year, making cancer a leading cause of pre-mature mortality in the world. The main hallmarks of severe eye conditions (i.e angiogenesis, inflammation and vascular permeability) play also pivotal roles in cancer, being therapeutic targets to treat both kind of diseases.
The overall goal of 3D-NEONET is the improvement of available treatments for cancer and ocular disease by enhancing drug discovery-development and delivery to targeted tissues, through advanced international co-operation between academic and non-academic partners. The interdisciplinary expertise provided by 18 partners in 7 countries encompasses among others: drug screens, ADME, toxicology, preclinical models, nanotechnology, biomaterials and clinical trials.
After the success with ongoing FP7-IAPP project 3D-NET (Drug Discovery and Development of Novel Eye Therapeutics; (www.ucd.ie/3dnet), we are assembling 3D-NEONET, this enlarged European interdisciplinary consortium that will join forces and exchange skills to enhance current therapies in oncology and ophthalmology.
The 3 global objectives of 3D-NEONET are:
1- Enhance the discovery and development of novel drugs, targets and biomarkers for ophthalmology and oncology.
2- Improve the Delivery of Therapeutics for Oncology and Ophthalmology
3- Enhancement of Research, Commercial and Clinical Trial Project Management Practices in these fields.
Through participation in the program, 3D-NEONET is the vehicle for driving synergies between academic and non-academic participants leading to increased scientific and technological excellence as well as tangible innovative outputs that will strengthen the competitiveness of both the researchers and industries of the network even beyond the lifetime of the network.
The overall goal of 3D-NEONET is the improvement of available treatments for cancer and ocular disease by enhancing drug discovery-development and delivery to targeted tissues, through advanced international co-operation between academic and non-academic partners. The interdisciplinary expertise provided by 18 partners in 7 countries encompasses among others: drug screens, ADME, toxicology, preclinical models, nanotechnology, biomaterials and clinical trials.
After the success with ongoing FP7-IAPP project 3D-NET (Drug Discovery and Development of Novel Eye Therapeutics; (www.ucd.ie/3dnet), we are assembling 3D-NEONET, this enlarged European interdisciplinary consortium that will join forces and exchange skills to enhance current therapies in oncology and ophthalmology.
The 3 global objectives of 3D-NEONET are:
1- Enhance the discovery and development of novel drugs, targets and biomarkers for ophthalmology and oncology.
2- Improve the Delivery of Therapeutics for Oncology and Ophthalmology
3- Enhancement of Research, Commercial and Clinical Trial Project Management Practices in these fields.
Through participation in the program, 3D-NEONET is the vehicle for driving synergies between academic and non-academic participants leading to increased scientific and technological excellence as well as tangible innovative outputs that will strengthen the competitiveness of both the researchers and industries of the network even beyond the lifetime of the network.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/734907 |
| Start date: | 01-01-2017 |
| End date: | 30-06-2022 |
| Total budget - Public funding: | 945 000,00 Euro - 945 000,00 Euro |
Cordis data
Original description
Severe ocular disorders are affecting the lives of more than 100Mill people world-wide and at least 25% of the population above 70 years of age, a growing demographic group in EU. More than 8 million people lose their lives to cancer every year, making cancer a leading cause of pre-mature mortality in the world. The main hallmarks of severe eye conditions (i.e angiogenesis, inflammation and vascular permeability) play also pivotal roles in cancer, being therapeutic targets to treat both kind of diseases.The overall goal of 3D-NEONET is the improvement of available treatments for cancer and ocular disease by enhancing drug discovery-development and delivery to targeted tissues, through advanced international co-operation between academic and non-academic partners. The interdisciplinary expertise provided by 18 partners in 7 countries encompasses among others: drug screens, ADME, toxicology, preclinical models, nanotechnology, biomaterials and clinical trials.
After the success with ongoing FP7-IAPP project 3D-NET (Drug Discovery and Development of Novel Eye Therapeutics; (www.ucd.ie/3dnet), we are assembling 3D-NEONET, this enlarged European interdisciplinary consortium that will join forces and exchange skills to enhance current therapies in oncology and ophthalmology.
The 3 global objectives of 3D-NEONET are:
1- Enhance the discovery and development of novel drugs, targets and biomarkers for ophthalmology and oncology.
2- Improve the Delivery of Therapeutics for Oncology and Ophthalmology
3- Enhancement of Research, Commercial and Clinical Trial Project Management Practices in these fields.
Through participation in the program, 3D-NEONET is the vehicle for driving synergies between academic and non-academic participants leading to increased scientific and technological excellence as well as tangible innovative outputs that will strengthen the competitiveness of both the researchers and industries of the network even beyond the lifetime of the network.
Status
CLOSEDCall topic
MSCA-RISE-2016Update Date
28-04-2024
Images
No images available.
Geographical location(s)
Structured mapping
Search
Organisations
-
| University College Dublin (UCD) (Coördinator)
-
| ASHLAND SPECIALTIES IRELAND LIMITED
-
| BIOREPERIA AB
-
| BLAFAR LIMITED
-
| CRESSET BIOMOLECULAR DISCOVERY LIMITED
-
| ECM INGENIERIA AMBIENTAL SL
-
| EXPERIMENTELLE PHARMAKOLOGIE UND ONKOLOGIE BERLIN-BUCH GMBH
-
| EYECRO LLC
-
| HGBEYOND MATERIALS SICENCE SL
-
| ICON CLINICAL RESEARCH LIMITED
-
| Karlsruhe Institute of Technology
-
| LABORATORIO IBERICO INTERNACIONAL DE NANOTECNOLOGIA (LIN INL)
-
| LINKOPINGS UNIVERSITET
-
| NATIONAL UNIVERSITY OF IRELAND GALWAY (NUI Galway)
-
| OCUPHARM DIAGNOSTICS SL